Portal de Periódicos da CAPES

A Neu View of Invasive Lobular Breast Cancer

2013; American Association for Cancer Research; Volume: 19; Issue: 13 Linguagem: Inglês

10.1158/1078-0432.ccr-13-1031

1557-3265

Ron Bose,

Monoclonal and Polyclonal Antibodies Research

Genome sequencing of relapsed, invasive lobular breast cancer identified actionable mutations in 86% of the cases. HER2 alterations occur in 27% of the cases, including 4 cases with activating HER2 mutations and 1 with a novel HER2-GRB7 gene fusion. This fusion links the HER2 tyrosine kinase domain to the GRB7 src homology 2 (SH2) domain.